Pharvaris Provides Business Update and Expands Development Program for Deucrictibant
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
Pharvaris B.V. (PHVS) PT Raised to $42 at Oppenheimer
September 6, 2024 5:07 AM EDTOppenheimer analyst Justin Kim raised the price target on Pharvaris B.V. (NASDAQ: PHVS) to $42.00 (from $38.00) while maintaining a Outperform rating.
The analyst comments "On Thursday PHVS presented 2 oral presentations and 10 posters at the bradykinin symposium focused on HAE. Critical to the PHVS... More
